Senate Judiciary Committee Chairman Richard Durbin (D-IL). Photo: Diego M. Radzinschi/ALM

The U.S. Food and Drug Administration is under pressure to boost oversight of online prescription drug promotions amid the rise of social media influencers and their potential to convey misinformation to vulnerable patients and impressionable teens.

Whether demands from some in the medical community and in Congress will spur new FDA guidance and greater enforcement, FDA-regulated companies should consider reviewing their policies and practices pertaining to influencers they engage, attorneys in the field say.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employee Participation
Employee-Paid
Employer-Paid